Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: Potential effects on clinical safety and efficacy

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 1-13

  Hochhaus, Günther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

glucocorticoid receptor; intranasal corticosteroids; mometasone furoate; pharmacodynamics; pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MOMETASONE FUROATE; NEDOCROMIL; OSTEOCALCIN; STEROID; TRIAMCINOLONE ACETONIDE;

ADRENAL INSUFFICIENCY; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGY; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; BONE MASS; CUSHING SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FIRST PASS EFFECT; GENE REPRESSION; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; NONHUMAN; RAT; RECEPTOR AFFINITY; SIDE EFFECT; TH1 CELL; TH2 CELL; TRANSCRIPTION INITIATION;

ADMINISTRATION, INTRANASAL; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; HISTAMINE; HUMANS; LEUKOCYTES; MOLECULAR STRUCTURE; NASAL MUCOSA; PREGNADIENEDIOLS; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TRANSCRIPTIONAL ACTIVATION;

EID: 45149130619     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.005     Document Type: Article

References (110)

1. The Allergy Report Vol. 2 (2000), American Academy of Allergy, Asthma and Immunology, Milwaukee, Wisc
2. Bousquet J., Van Cauwenberge P., Bachert C., et al., for the European Academy of Allergy and Clinical Immunology (EAACI) and the Allergic Rhinitis and its Impact on Asthma (ARIA) Groups. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58 (2003) 192-197
3. Trangsrud A., Whitaker A., and Small R. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 22 (2002) 1458-1467
4. Smith C., and Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48 (1998) 956-960
5. Nasonex nasal spray [package insert] (2005), Schering Corporation, Kenilworth, NJ
6. Hochhaus G., Sahasranaman S., Derendorf H., and Möllmann H. Intranasal glucocorticoid delivery: Competition between local and systemic effects. STP Pharma Sciences 12 (2002) 23-31
7. Crim C., Pierre L., and Daley-Yates P. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 23 (2001) 1339-1354
8. Mandl M., Nolop K., Lutsky B., and for the 194-079 Study Group. Ann Allergy Asthma Immunol 79 (1997) 370-378
9. Gawchik S., Goldstein S., and Prenner B John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 90 (2003) 416-421
10. Small C., Hernandez J., Reyes A., et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 116 (2005) 1275-1281
11. Meltzer E., Bachert C., and Staudinger H. Treating acute rhi-nosinusitis: Comparing efficacy and safety of mometa-sone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 116 (2005) 1289-1295
12. Bodor N., and Buchwald P. Corticosteroid design for the treatment of asthma: Structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12 (2006) 3241-3260
13. Popper T., Gentles M., Kung T., et al. Structure-activity relationships of a series of novel topical corticosteroids. J Steroid Biochem 27 (1987) 837-843
14. Issar M., Sahasranaman S., Buchwald P., and Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 27 (2006) 511-516
15. Biggadike K., and Bledsoe R. Fluticasone furoate-enhanced affinity for the glucocorticoid receptor: Receptor crystal structure and route of metabolic in-activation. Presented at: 25th Congress of the European Academy of Allergology and Clinical Immunology (June 10-14, 2006) Vienna, Austria
16. Sharpe M., and Jarvis B. Inhaled mometa-sone furoate: A review of its use in adults and adolescents with persistent asthma [published correction appears in Drugs. 2001;61:1544]. Drugs 61 (2001) 1325-1350
17. Umland S., Schleimer R., and Johnston S. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 15 (2002) 35-50
18. Gupta R., Jindal D., and Kumar G. Corticosteroids: The mainstay in asthma therapy. Bioorg Med Chem 12 (2004) 6331-6342
19. Hochhaus G., Rohdewald P., Möllmann H., and Greschuchna D. Identification of glucocorticoid receptors in normal and neoplastic adult human lung. Res Exp Med (Berl) 182 (1983) 71-78
20. Dahlberg E., Thalén A., Brattsand R., et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol 25 (1984) 70-78
21. Rohdewald P., Möllmann H., and Hochhaus G. Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions 17 (1986) 290-291
22. Druzgala P., Hochhaus G., and Bodor N. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Lote-prednol etabonate. Soft drugs-10. J Steroid Biochem Mol Biol 38 (1991) 149-154
23. Noon J., Evans C., Haynes W., et al. A comparison of techniques to assess skin blanching following topical application of glucocorticoids. Br J Dermatol 134 (1996) 837-842
24. Stellato C., Atsuta J., Bickel C., and Schleimer R. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 104 (1999) 623-629
25. Högger P., and Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 59 (1994) 597-602
26. Sahasranaman S., Issar M., Tóth G., et al. Characterization of degrada-tion products of mometasone furo-ate. Pharmazie 59 (2004) 367-373
27. Valotis A., Neukam K., Elert O., and Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 93 (2004) 1337-1350
28. Austin R., Maschera B., Walker A., et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J 20 (2002) 1386-1392
29. Valotis A., and Högger P. Significant receptor affinities of metabolites and a degradation product of mometa-sone furoate. Respir Res 5 (2004) 7
30. Belvisi M., Bundschuh D., Stoeck M., et al. Preclinical profile of ci-clesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 314 (2005) 568-574
31. Sahasranaman S., Issar M., and Hochhaus G. Metabolism of mometasone furo-ate and biological activity of the metabolites. Drug Metab Dispos 34 (2006) 225-233
32. Corren J. Intranasal corticosteroids for allergic rhinitis: How do different agents compare?. J Allergy Clin Immunol 104 (1999) S144-S149
33. O'Connor B., Bonnaud G., Haahtela T., et al. Dose-ranging study of mometa-sone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 86 (2001) 397-404
34. Hochhaus G., Möllmann H., Derendorf H., and Gonzalez-Rothi R. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37 (1997) 881-892
35. Barnes P. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 148 (2006) 245-254
36. Reichardt H., Tuckermann J., et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. Embo J 20 (2001) 7168-7173
37. Jantzen H., Strähle U., and Gloss B. Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell 49 (1987) 29-38
38. Rigaud G., Roux J., Pictet R., and Grange T. In vivo footprinting of rat TAT gene: Dynamic interplay between the glucocorticoid receptor and a liver-specific factor. Cell 67 (1991) 977-986
39. Schäcke H., Schottelius A., Döcke W., et al. Dissociation of transacti-vation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101 (2004) 227-232
40. Roumestan C., Henriquet C., Bousquet J., and Mathieu M. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy 33 (2003) 895-901
41. Allen D. Systemic effects of intranasal steroids: An endocrinologist's perspective. J Allergy Clin Immunol 106 Suppl 4 (2000) S179-S190
42. Thorsson L., Borgâ O., and Edsbäcker S. Systemic availability of budesonide after nasal administration of three different formulations: Pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol 47 (1999) 619-624
43. Edsbäcker S., Andersson K., and Ryrfeldt A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 29 (1985) 477-481
44. Lumry W. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis [published correction appears in J Allerg/ Clin Immunol. 2000;105:394]. J Allergy Clin Immunol 104 (1999) S150-S158
45. Richards D., and Daley-Yates P. Choice of inhaled and intranasal steroids when used in combination for asthma and rhinitis in children. Allergy 55 Suppl (2000) A185 Abstract
46. Daley-Yates P., and McAllister T. Systemic bioavailability of fluticasone propionate administered as nasal drops (FP-Drops) and aqueous nasal spray formulations (FPANS). Allergy 53 (1998) 158 Abstract
47. Edsbäcker S., and Brattsand R. Budeso-nide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Ann Allergy Asthma Immunol 88 (2002) 609-616
48. Baroody F., Ford S., Proud D., et al. Relationship between histamine and physiological changes during the early response to nasal antigen provocation. J Appl Physiol 86 (1999) 659-668
49. Berridge M., Heald D., Muswick G., et al. Biodistribution and kinetics of nasal carbon-11-triamcinolone ace-tonide. J Nucl Med 39 (1998) 1972-1977
50. Pedersen S., and O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52 Suppl 39 (1997) 1-34
51. Bacharier L., Raissy H., Wilson L., et al. Long-term effect of budes-onide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma. Pediatrics 113 (2004) 1693-1699
52. Allen D. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 25 (1996) 699-717
53. Unterman T., and Phillips L. Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 61 (1985) 618-626
54. Jennings B., Andersson K., and Johansson S. Assessment of systemic effects of inhaled glucocorti-costeroids: Comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 40 (1991) 77-82
55. Stead R., Horsman A., Cooke N., et al. Bone mineral density in women taking inhaled corticosteroids. Thorax 45 (1990) 792 Abstract
56. König P., Hillman L., Cervantes C., et al. Bone metabolism in children with asthma treated with inhaled be-clomethasone dipropionate. J Pediatr 122 (1993) 219-226
57. Martinati L., Bertoldo F., Gasperi E., et al. Effect on cortical and trabec-lar bone mass of different anti-inflammatory treatments in preado-lescent children with chronic asthma. Am J Respir Crit Care Med 153 (1996) 232-236
58. Skoner D., Rachelefsky G., et al. Detection of growth sup-pression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105 (2000) E23
59. Perry R., Findlay C., and Donaldson M. Cushing's syndrome, growth impairment, and occult adrenal suppression associated with intranasal steroids. Arch Dis Child 87 (2002) 45-48
60. Daley-Yates P., Kunka R., Yin Y., et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 60 (2004) 265-268
61. Daley-Yates P., and Richards D. Pharmacokinetic and pharmacodynamic relationships for intranasal corticosteroids. J Allergy Clin Immunol 107 Suppl (2001) S313 Abstract 1023
62. Daley-Yates P., Price A., Sisson J., et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51 (2001) 400-409
63. Lipworth B., and Jackson C. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium. Drug Saf 23 (2000) 11-33
64. Teng X., Cutler D., and Davies N. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos 24 (2003) 321-333
65. Tayab Z., Fardon T., Lee D., et al. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of flutica-sone propionate and mometasone furoate. Br J Clin Pharmacol 64 (2007) 698-705
66. Zbaida S., Shannon D., Du Y., et al. In vitro metabolism of mometasone furoate. Faseb J 11 Suppl S (1997) 339 Abstract A829
67. Affrime M., and Kosoglou T. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma. J Allergy Clin Immunol 107 Suppl (2001) S104 Abstract 346
68. Kripalani K., Cohen A., Weliky I., and Schreiber E. Metabolism of triamcinolone acetonide-21-phosphate in dogs, monkeys, and rats. J Pharm Sci 64 (1975) 1351-1359
69. Mueller U., and Potter J. Enterohe-patic circulation of prednisolone in rats. Res Commun Chem Pathol Pharmacol 32 (1981) 195-206
70. Khalafallah N., and Jusko W. Tissue distribution of prednisolone in the rabbit. J Pharmacol Exp Ther 229 (1984) 719-725
71. Nasacort AQ nasal spray [package insert] (2006), Sanofi-Aventis, Bridgewater, NJ
72. Beconase AQ nasal spray [package insert] (2005), GlaxoSmithKline, Research Triangle Park, NC
73. Flonase nasal spray [package insert] (2004), GlaxoSmithKline, Research Triangle Park, NC
74. Nasarel nasal spray [package insert] (2002), Ivax Laboratories, Inc, Miami, Fla
75. Rohatagi S., Bye A., Falcoz C., et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 36 (1996) 938-941
76. Rohatagi S., Hochhaus G., Mollmann H., et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 35 (1995) 1187-1193
77. Peets E., Staub M., and Symchowicz S. Plasma binding of betamethasone-3H, dexamethasone-3H, and corticosol-14C-a comparative study. Biochem Pharmacol 18 (1969) 1655-1663
78. Ryrfeldt A., Andersson P., Edsbäcker S., et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 122 (1982) 86-95
79. McDowall J., Mackie A., Ventresca G., and Bye A. Pharmacokinetics and bioavailability of intranasal fluticasone in humans. Clin Drug Invest 14 (1997) 44-52
80. Rohatagi S., Appajosyula S., Derendorf H., et al. Risk-benefit value of inhaled glucocorticoids: A pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44 (2004) 37-47
81. Davies R., and Nelson H. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 19 (1997) 27-38 discussion 2-3
82. Brannan M., Seiberling M., Cutler D., et al. Lack of systematic activity with intranasal mometasone furoate. J Allergy Clin Immunol 97 Suppl (1996) 198 Abstract 62
83. Brannan M., Herron J., and Affrime M. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 19 (1997) 1330-1339
84. Meltzer E., Berger W., Berkowitz R., et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 104 (1999) 107-114
85. Schenkel E., Skoner D., Bronsky E., et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105 (2000) E22
86. Agertoft L., and Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budes-onide. J Allergy Clin Immunol 104 (1999) 948-952
87. Lee D., Robb F., Sims E., et al. Systemic bioactivity of intranasal tri-amcinolone and mometasone in perennial allergic rhinitis. Br J Clin Pharmacol 55 (2003) 310-313
88. van Drunen C., Meltzer E., Bachert C., et al. Nasal allergies and beyond: A clinical review of the pharmacology, efficacy, and safety of mometa-sone furoate [published correction appears in Allergy. 2005;60:1335]. Allergy 60 Suppl 80 (2005) 5-19
89. Naclerio R. Allergic rhinitis. N Engl J Med 325 (1991) 860-869
90. Ciprandi G., Pronzato C., Ricca V., et al. Evidence of intercellular adhesion molecule-1 expression on nasal epithelial cells in acute rhinoconjunc-tivitis caused by pollen exposure. J Allergy Clin Immunol 94 (1994) 738-746
91. Skoner D. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108 Suppl 1 (2001) S2-S8
92. Mygind N., Nielsen L., Hoffman H., et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 108 Suppl 1 (2001) S16-S25
93. Frieri M., Therattil J., Chavarria V., et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 81 (1998) 431-437
94. Berkowitz R., Roberson S., Zora J., et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20 (1999) 167-172
95. Schleimer R., Schulman E., MacGlashan Jr. D., et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 71 (1983) 1830-1835
96. Bradding P., Feather I., Wilson S., et al. Cytokine immunoreactivity in seasonal rhinitis: Regulation by a topical corticosteroid. Am J Respir Crit Care Med 151 (1995) 1900-1906
97. Levenson T., and Greenberger P. Immunologic effects of intranasal corticosteroids. Allergy Asthma Proc 17 (1996) 157-159
98. Fokkens W., Godthelp T., Holm A., et al. Allergic rhinitis and inflam-mation: The effect of nasal cortico-steroid therapy. Allergy 52 Suppl 36 (1997) 29-32
99. Meltzer E. The pharmacological basis treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 52 Suppl 36 (1997) 33-40
100. Fokkens W., Godthelp T., Holm A., and Klein-Jan A. Local corticosteroid treatment: The effect on cells and cytokines in nasal allergic inflammation. Am J Rhinol 12 (1998) 21-26
101. Umland S., Nahrebne D., Razac S., et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 100 (1997) 511-519
102. Mosmann T., and Coffman R. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to dif-ferent functional properties. Annu Rev Immunol 7 (1989) 145-173
103. Corrigan C., and Kay A. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 13 (1992) 501-507
104. Naclerio R., Meier H., Kagey-Sobotka A., et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 128 (1983) 597-602
105. Ciprandi G., Tosca M., Passalacqua G., and Canonica G. Intranasal mo-metasone furoate reduces latephase inflammation after allergen challenge. Ann Allergy Asthma Immunol 86 (2001) 433-438
106. Janka-Junttila M., Moilanen E., Hasala H., et al. The glucocorticoid RU24858 does not distinguish between transrepression and trans-activation in primary human eosinophils. J Inflamm (Lond) 3 (2006) 10
107. Meltzer E., Jalowayski A., Orgel H., and Harris A. Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 102 (1998) 39-49
108. Calderón E., and Lockey R. A possible role for adhesion molecules in asthma. J Allergy Clin Immunol 90 (1992) 852-865
109. Sugimoto Y., Ogawa M., Tai N., and Kamei C. Inhibitory effects of glucocorticoids on rat eosinophil superoxide generation and chemotaxis. Int Immunopharmacol 3 (2003) 845-852
110. Zhang X., Moilanen E., Adcock I., et al. Divergent effect of mometa-sone on human eosinophil and neutrophil apoptosis. Life Sci 71 (2002) 1523-1534